Company news

Clarity Pharmaceuticals Ltd. news in 2026

Clarity Pharmaceuticals Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 30, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 30, 2026

Ph III CLARIFY trial target number of participants achieved

October 26, 2026

Notice of Annual General Meeting/Proxy Form

October 22, 2026

Ceasing to be a substantial holder

October 20, 2026

SAR-bisPSMA Presentation - Drug & Device Conference

October 12, 2026

SECuRE update

October 7, 2026

Becoming a substantial holder

October 5, 2026

Corporate governance statement

September 30, 2026

Appendix 4G

September 30, 2026

Annual Report to shareholders

September 30, 2026

Ceasing to be a substantial holder

September 24, 2026

Becoming a substantial holder

September 22, 2026

Date of Annual General Meeting 25 November 2026

September 20, 2026

Preliminary Final Report

August 26, 2026

Becoming a substantial holder

August 24, 2026

Ceasing to be a substantial holder

August 12, 2026

Becoming a substantial holder

August 7, 2026

Ceasing to be a substantial holder

August 6, 2026

Bioshares Biotech Summit Presentation

August 5, 2026

Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses

August 5, 2026

Becoming a substantial holder

August 5, 2026

Notification regarding unquoted securities - CU6

August 5, 2026

SECuRE update

August 4, 2026

Ceasing to be a substantial holder

July 31, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 30, 2026

Becoming a substantial holder

July 30, 2026

Data on SAR-bisPSMA to be presented at EANM

June 28, 2026

Clarity receives $9.8 million R&D tax incentive refund

May 14, 2026

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

April 14, 2026

Clarity signs a Commercial Manufacturing Agreement

April 13, 2026

Co-PSMA data published in the European Urology journal

March 31, 2026

Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics

March 25, 2026

Clarity signs a large-scale Manufacturing Supply Agreement

March 24, 2026

Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

March 17, 2026

Co-PSMA data presented

March 16, 2026

Registrational Phase III AMPLIFY trial: Target number of participants achieved

March 10, 2026

AMPLIFY trial - Target number of participants achieved

March 9, 2026

Half Yearly Report and Accounts

February 26, 2026

SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET

February 23, 2026

SECuRE trial update

February 22, 2026

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

February 16, 2026

Co-PSMA abstract released

February 15, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 30, 2026

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

January 15, 2026

SECuRE trial to continue with no modifications to protocol

January 14, 2026

Decks in 2026